Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy]acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 3, 1999, Pages 1117-1124

  Snyder, David W ^a   Bach, Nicholas J ^a   Dillard, Robert D ^a   Draheim, Susan E ^a   Carlson, Donald G ^a   Fox, Niles ^a   Roehm, Neal W ^a   Armstrong, Christopher T ^a   Chang, Chan H ^a   Hartley, Lawrence W ^a   Johnson, Lea M ^a   Roman, Carlos R ^a   Smith, Amy C ^a   Song, Min ^a   Fleisch, Jerome H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[[3 (AMINOOXOACETYL) 2 ETHYL 1 (PHENYLMETHYL) 1H INDOL 4 YL]OXY]ACETATE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GUINEA PIG; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG LAVAGE; NONHUMAN; PLEURA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RABBIT;

ACETIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CELL LINE; CLONING, MOLECULAR; CRICETINAE; GUINEA PIGS; HUMANS; INDOLES; MALE; MESOCRICETUS; MICE; MICE, TRANSGENIC; MUSCLE, SMOOTH; PHOSPHOLIPASES A; PLEURA; RABBITS; RATS; RECOMBINANT PROTEINS; THROMBOXANE A2;

EID: 0033022376     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Béréziat G, Voelker DR, Wolf C and Touqui L (1998) Generation of lysophospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest 102:1152-1160.
2. 2. J Med Chem 37:557-559.
3. 2 produced in baculovirus-infected insect cells. Biol Technology 12:69-74.
4. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW and Chan C-C (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74.
5. 2. 1. Indole-3-acetamides. J Med Chem 39:5119-5136.
6. 2. 3. Indole-3-glyoxamides. J Med Chem 39:5159-5175.
7. 2 inhibitor. J Pharmacol Exp Ther 278:252-257.
8. 2 inhibitors. Eur J Pharmacol 308:195-203.
9. 2). Agents Actions 39:C30-C32.
10. 2 in vesicles. Biochemistry 28:4135-4139.
11. 2 gene in inbred mouse strains. J Biol Chem 270:22378-22385.
12. 2 in synovial fluid and serum in acute arthritis. Scand J Rheumatol 23:68-72.
13. 2 in human platelets. J Biol Chem 266:26796-26804.
14. Mio-induced intestinal neoplasia. Cell 81:957-966.
15. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC and Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.
16. 2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther 274:1254-1262.
17. 2 inhibitors, in Basic and Clinical Aspects in Inflammatory Diseases (Uhl W, Nevalainen TJ and Buchler MW eds) pp 140-145, Karger, Basel.
18. 2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am J Gastroenterol 88:1076-1080.
19. 2 in colonie mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35:1593-1598.
20. 2 in serum from patients with severe acute pancreatitis. Gut 34:1133-1136.
21. 2 in human serum. Clin Chem 38:1824-1829.
22. Prasit P, Black WC, Chan C-C, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay D, Kargman S, Lau CK, Li C-S, Mancini J, Ouimet N, Roy P, Tagari P, Vickers P, Wong E, Young RN and Zamboni R (1995) L-745,337: A selective cyclooxygenase-2 inhibitor. Med Chem Res 5:364-374.
23. 2 in the physiopathology of osteoarthritis. J Rheumatol 18:117-119.
24. 2 on short chain phosphatidylcholine-mixed micelles: Development of a spectrophotometric assay suitable for a microtiterplate reader. Analyt Biochem 204:190-197.
25. 2. Anal Biochem 217:25-32.
26. 2 in sera of febrile patients with microbiologically or clinically documented infections Clin Infect Dis 17:864-870.
27. 2 catalytic activity concentration in human serum and ascities. J Clin Chem Biochem 25:505-509.
28. 2. Nat Struct Biol 2:458-465.
29. 2 s on guinea pig lung pleural strips. J Pharmacol Exp Ther 266:1147-1155.
30. Tibes U and Friebe W-G (1997) Phospholipase A2 inhibitors in development. Exp Opin Invest Drugs 6:279-298.
31. Tramposch KM, Steiner SA, Stanley PL, Nettleton DO, Franson RC, Lewin AH and Carroll FI (1992) Novel inhibitor of phospholipase A2 with topical anti-inflammatory activity. Biochem Biophys Res Commun 189:272-279.
32. 2 in the pathobiology of disease. Lab Invest 55:391-404.
33. 2 expression and pathogenesis of the sepsis syndrome. Circ Shock 39:160-167.
34. van Rossum JM (1963) Cumulative dose-response curves. II. Techniques for the making of dose response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143:299-330.
35. Waud DR (1976) Analysis of dose-response relationships, in Advances in General and Cellular Pharmacology (Narahashi T and Bianchi CP eds) pp 145-178, Plenum Press, New York.
36. 2. J Clin Invest 97:250-257.
37. 2 in concert with polymorphonuclear leukocytes. J Biol Chem 269:26331-27337.
38. 2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate. J Biol Chem 285:6675-6681.